if we have good clinical data by then, then it'd be abnormal not...

if we have good clinical data by then, then it'd be abnormal not to have at least an equivalent valuation to our nearest competitor - say Alnylam.

that'd be roughly $50 pps.

also, that'd be conservative given alny's good clinical data in far smaller target markets than Benitec's pipeline.

and Cool would be the first person in history to deliver a prediction ahead on time and budget, given he originally forecast 2017.